Foghorn Therapeutics (FHTX) Research & Development (2019 - 2026)

Foghorn Therapeutics' Research & Development history runs 8 years deep, the most recent figure standing at $18.3 million for Q1 2026.

• In Q1 2026, Research & Development fell 15.57% year-over-year to $18.3 million; the TTM figure through Mar 2026 stood at $82.1 million (down 9.4% YoY), while the FY2025 annual figure was $85.5 million, down 9.59% from the prior year.
• Research & Development was $18.3 million for Q1 2026 at Foghorn Therapeutics, down from $22.0 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $30.0 million in Q1 2023 to a low of $18.3 million in Q1 2026.
• Historically, Research & Development has averaged $24.3 million across 5 years, with a median of $24.5 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 39.33% in 2022, then slipped 18.98% in 2025.
• A 5-year view of Research & Development shows it stood at $28.2 million in 2022, then decreased by 14.19% to $24.2 million in 2023, then slipped by 15.27% to $20.5 million in 2024, then increased by 7.5% to $22.0 million in 2025, then fell by 17.18% to $18.3 million in 2026.
• The last three Research & Development figures came in at $18.3 million (Q1 2026), $22.0 million (Q4 2025), and $20.0 million (Q3 2025), per Business Quant data.